-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The prognostic value of neogenitive granulocyte-to-lymphocyte ratio (NLR) for patients with pulmonary large cell neuroendocrine cancer (LCNEC) is not yet clear.
, researchers conducted a retrospective study to assess the relationship between pre-treatment NLR and clinical outcomes in patients with advanced LCNEC, as well as the effects of immuno-related tumor microeconients (TME), in a recent study published in British Journal of Cancer, an authoritative journal in the field of oncology.
retrospective study included 63 patients with advanced LCNEC who received chemotherapy.
researchers collected clinical data from subjects and investigated TME status (CD4, CD8, CD20, and FOXP3).
survival of patients with low NLR (-lt;5) was significantly higher than that of patients with high NLR (≥5) (14.9 vs. 5.2 months; p.lt;0.001).
multi-factor analysis shows that higher NLRs can predict poor prognostics (HR is 3.43; 95% CI is 1.73-6.79; p.lt;0.001).
NLR was negatively corred with tumor and substring CD8-positive tumor-soaked lymphocytes (tumors: r=0.648, p=0.005, substitly: r=-0.490, p=0.046).
can be seen that high NLR is associated with poor prognostics in patients with advanced LCNEC.
the results of this study show that NLR can reflect TME at least partially, suggesting that NLR not only acts as a clinical prognosmation indicator, but also serves as an indicator of tumor immune status.
。